作者
Ziad Bakouny, Emre Yekedüz, David A Braun, Jacob E Berchuck, Laure Hirsch, Güngör Utkan, Yi Lee, Quoc-Dien Trinh, Toni K Choueiri, Yüksel Ürün
发表日期
2021/10/1
来源
Critical reviews in oncology/hematology
卷号
166
页码范围
103463
出版商
Elsevier
简介
Introduction
Novel non-steroidal anti-androgens (NSAA) are increasingly part of the management of prostate cancer. We aimed to quantify and compare the neurologic side effects of NSAA agents.
Materials and methods
Phase III randomized controlled trials evaluating NSAAs in the treatment of prostate cancer were selected by two reviewers independently in MEDLINE. A random-effects model and the Mantel-Haenszel method were used. The Odds Ratio (OR) and its 95 % confidence interval were computed. The primary endpoints were the rates of neurologic adverse events.
Results
Eight phase III trials evaluating novel NSAAs (vs. non-NSAAs) were included. Fatigue (OR:1.66 [1.32–2.08]), falls (OR:1.76 [1.25–2.49]), headache (OR:1.74 [1.42–2.14]), and dizziness (OR:1.70 [1.33–2.19]) were found to be significantly associated with NSAA use.
Conclusions
NSAAs are associated with an increase in various …
学术搜索中的文章
Z Bakouny, E Yekedüz, DA Braun, JE Berchuck… - Critical reviews in oncology/hematology, 2021